Related Experiment Video
Updated: Mar 21, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Loss of Dnmt3b accelerates MLL-AF9 leukemia progression
1State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Abstract:
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic disorder with a poor prognosis. Abnormal DNA methylation is involved in the initiation and progression of AML. The de novo methyltransferases Dnmt3a and Dnmt3b are responsible for the generation of genomic methylation patterns. While DNMT3A is frequently mutated in hematological malignancies, DNMT3B is rarely mutated. Although it has been previously reported that Dnmt3b functions as a tumor suppressor in a mouse model of Myc-induced lymphomagenesis, its function in AML is yet to be determined. In this study, we demonstrated that deletion of Dnmt3b accelerated the progression of MLL-AF9 leukemia by increasing stemness and enhancing cell cycle progression. Gene profiling analysis revealed upregulation of the oncogenic gene set and downregulation of the cell differentiation gene set. Furthermore, loss of Dnmt3b was able to synergize with Dnmt3a deficiency in leukemia development. Taken together, these results demonstrate that Dnmt3b plays a tumor suppressive role in MLL-AF9 AML progression, thereby providing new insights into the roles of DNA methylation in leukemia development.
Insights
DNA methyltransferase 3B (Dnmt3b) deletion accelerated MLL-AF9 acute myeloid leukemia (AML) progression by increasing stemness and cell cycle activity. Dnmt3b acts as a tumor suppressor in AML.
Area of Science:
- Epigenetics
- Hematopoiesis
- Oncology
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer with poor outcomes.
- Aberrant DNA methylation is a key factor in AML development and progression.
- The roles of DNA methyltransferases, particularly Dnmt3b, in AML remain unclear.
Purpose of the Study:
- To investigate the function of Dnmt3b in MLL-AF9 induced AML.
- To determine if Dnmt3b acts as a tumor suppressor or oncogene in AML.
Main Methods:
- Mice with Dnmt3b deletion were used to study MLL-AF9 leukemia progression.
- Gene profiling analysis was performed to assess gene expression changes.
- Synergistic effects with Dnmt3a deficiency were examined.
Main Results:
- Deletion of Dnmt3b accelerated MLL-AF9 leukemia progression.
- Loss of Dnmt3b increased cancer stemness and cell cycle progression.
- Gene profiling showed oncogene upregulation and differentiation gene downregulation.
- Dnmt3b deficiency synergized with Dnmt3a deficiency in leukemia development.
Conclusions:
- Dnmt3b plays a significant tumor suppressive role in MLL-AF9 AML.
- These findings offer new insights into DNA methylation's role in leukemia.
- Targeting Dnmt3b could be a potential therapeutic strategy for AML.
